sunitinib mylan 37,5 mg tvrde kapsule
mylan ireland limited, unit 35/36 grange parade, baldoyle industrial estate, dublin 13, irska - сунитиниб - kapsula, tvrda - 37,5 mg - urbroj: jedna kapsula sadrži 37,5 mg sunitiniba
sunitinib mylan 50 mg tvrde kapsule
mylan ireland limited, unit 35/36 grange parade, baldoyle industrial estate, dublin 13, irska - сунитиниб - kapsula, tvrda - 50 mg - urbroj: jedna kapsula sadrži 50 mg sunitiniba
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
arsenic trioxide mylan
mylan ireland limited - Триоксид arsen - leukemija, promyelocytic, akutna - antineoplastična sredstva - Триоксид arsen mylan u indiciran za indukciju remisije i konsolidacije kod odraslih pacijenata s je prvi put dijagnosticiran niski do srednji rizik akutne промиелоцитарной leukemije (ОПЛ) (bijelih krvnih stanica ≤ 10 x 103/Μl) u kombinaciji s trans-ретиноевая kiselina (ПТРК)- relaps/vatrostalne akutne промиелоцитарной leukemije (ОПЛ) (prethodni tretman treba da sadrže retinoid i kemoterapije), karakterizira t(15;17) translokacije i/ili dostupnost промиелоцитарный leukemije/ретиноевая kiselina receptora alfa (od pml/rar alfa) gena. brzina reakcije druge akutne mijeloične podtipovi leukemije do триоксида arsen ne beenexamined.
hulio
biosimilar collaborations ireland limited - adalimumab - hidradenitis suppurativa; psoriasis; uveitis; arthritis, rheumatoid; spondylitis, ankylosing; crohn disease; colitis, ulcerative; arthritis, psoriatic - imunosupresivima, faktor nekroze tumora alfa (tnf-α) inhibitori
eladynos
theramex ireland limited - abaloparatide - osteoporosis, postmenopausal; osteoporosis - homeostaza kalcija - liječenje osteoporoze kod žena u postmenopauzi s povećanim rizikom od prijeloma.
pandemic influenza vaccine h5n1 baxter ag
resilience biomanufacturing ireland limited - cjepivo protiv influence (cijeli virion, inaktivirano) koji sadrži antigen: a / vietnam / 1203/2004 (h5n1) - influenza, human; immunization; disease outbreaks - cjepiva - profilakcija gripe u službeno prijavljenoj pandemijskoj situaciji. cjepivo protiv influence pandemije treba koristiti u skladu s službenim smjernicama.
sorafenib mylan 200 mg filmom obložene tablete
mylan ireland limited, unit 35/36 grange parade, baldoyle industrial estate, dublin 13, irska - sorafenibtosilat - filmom obložena tableta - 200 mg - urbroj: jedna filmom obložena tableta sadrži 200 mg sorafeniba (u obliku tosilata)
meropenem mylan 1000 mg prašak za otopinu za injekciju/infuziju
mylan ireland limited, unit 35/36 grange parade, baldoyle industrial estate, dublin 13, irska - meropenem trihidrat - prašak za otopinu za injekciju / infuziju - urbroj: jedna bočica sadrži meropenem trihidrat što odgovara 1000 mg meropenema
meropenem mylan 500 mg prašak za otopinu za injekciju/infuziju
mylan ireland limited, unit 35/36 grange parade, baldoyle industrial estate, dublin 13, irska - meropenem trihidrat - prašak za otopinu za injekciju / infuziju - urbroj: jedna bočica sadrži meropenem trihidrat što odgovara 500 mg meropenema